Expert Review of Endocrinology & Metabolism最新文献_第5页

Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions. 脂肪营养不良综合征的药物治疗进展：目前的证据和未来的方向。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-11-05 DOI: 10.1080/17446651.2025.2574318

Ozge Besci, Merve Celik Guler, Maria Cristina Foss-Freitas, Elif Arioglu Oral

{"title":"Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions.","authors":"Ozge Besci, Merve Celik Guler, Maria Cristina Foss-Freitas, Elif Arioglu Oral","doi":"10.1080/17446651.2025.2574318","DOIUrl":"10.1080/17446651.2025.2574318","url":null,"abstract":"Introduction: Lipodystrophy syndromes are a heterogeneous group of rare disorders characterized by partial or generalized loss of adipose tissue, which may be either inherited or acquired. Loss of adipose tissue in typical storage sites starting from birth or later in life, combined with abnormal fat accumulation in other organs, contributes to multiple metabolic complications. There is currently no definitive cure available for lipodystrophy syndromes, and clinical management remains symptomatic.Areas covered: For this review, available databases were searched to identify publications and studies on current and emerging therapies to discuss the management of lipodystrophy syndromes. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment, while conventional therapies are used to target specific complications. Novel interventions are under investigation to address unmet clinical needs.Expert opinion: There is currently no cure for lipodystrophy syndromes. Emerging therapies are being investigated to expand therapeutic options and improve long-term outcomes of this complex disorder.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"565-592"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Basal insulin in the age of innovation: are diamonds still forever? 创新时代的基础胰岛素：钻石是否永恒？

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-10-25 DOI: 10.1080/17446651.2025.2580629

Theocharis Koufakis, Dimitrios Patoulias, Djordje S Popovic, Vasileios Tsimihodimos

{"title":"Basal insulin in the age of innovation: are diamonds still forever?","authors":"Theocharis Koufakis, Dimitrios Patoulias, Djordje S Popovic, Vasileios Tsimihodimos","doi":"10.1080/17446651.2025.2580629","DOIUrl":"10.1080/17446651.2025.2580629","url":null,"abstract":"Introduction: Basal insulin has long served as a cornerstone in the management of type 2 diabetes. However, the emergence of glucose-lowering agents with cardiometabolic benefits - such as glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and dual incretin receptor agonists - has prompted a reassessment of insulin's role in the modern therapeutic landscape.Areas covered: This article reviews recent evidence from cardiovascular outcomes trials and head-to-head studies comparing newer agents to basal insulin. A targeted literature search was conducted using PubMed and major diabetes guidelines to identify high-quality studies and recommendations. The discussion covers clinical scenarios where basal insulin remains essential, the benefits of combination therapy, and the impact of recent innovations such as once-weekly insulin formulations.Expert opinion: While modern therapies are increasingly prioritized due to superior efficacy, safety, and weight benefits, basal insulin remains indispensable for patients with advanced β-cell failure, symptomatic hyperglycemia, or contraindications to newer agents. Personalized, pathophysiology-driven strategies should guide therapy selection, including the integration of basal insulin where appropriate.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"471-474"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145370149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-12-11 DOI: 10.1080/17512433.2025.2594347

引用次数: 0

A research-based, current approach to diabetes-related acute foot infections and chronic osteomyelitis. 以研究为基础的糖尿病相关急性足部感染和慢性骨髓炎的当前方法。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-03-04 DOI: 10.1080/17446651.2025.2474110

Javier Aragón-Sánchez, Gerardo Víquez-Molina, Ilker Uçkay, José María Rojas-Bonilla, Benjamin A Lipsky

{"title":"A research-based, current approach to diabetes-related acute foot infections and chronic osteomyelitis.","authors":"Javier Aragón-Sánchez, Gerardo Víquez-Molina, Ilker Uçkay, José María Rojas-Bonilla, Benjamin A Lipsky","doi":"10.1080/17446651.2025.2474110","DOIUrl":"10.1080/17446651.2025.2474110","url":null,"abstract":"Introduction: Diabetic foot infections (DFIs) and diabetic foot osteomyelitis (DFO) are common and serious complications in patients with diabetes, often leading to severe morbidity (including amputation) and even mortality. Professional footcare, prompt diagnosis and appropriate treatment are crucial to preventing limb loss and improving outcomes in infections.Areas covered: This narrative review addresses the management of all DFIs, including the approach to clinical evaluation, appropriate diagnostic methods, and optimal therapeutic strategies. We specifically address key areas in antibiotic therapy, and surgical interventions and techniques. Based on our literature review and extensive, multidisciplinary experience, we developed a novel treatment flowchart specifically for the management of DFO.Expert opinion: Managing DFIs, including DFO, requires a multidisciplinary approach tailored to each patient's clinical presentation. While antibiotics, surgery, and wound care each play a crucial role, the decision-making process should always consider the infection's severity and chronicity. Our proposed flowchart for DFO management emphasizes the importance of logically-sequenced, easy to apply and tailored interventions to prevent unnecessary amputations and improve outcomes. Further research is needed to further refine this flowchart in clinical practice and demonstrate its effectiveness.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"481-495"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implications of the era of incretin-based weight loss therapy in menopause. 绝经期以肠促胰岛素为基础的减肥疗法的时代意义。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-07-30 DOI: 10.1080/17446651.2025.2540000

Santiago Palacios

引用次数: 0

Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial. 一项临床试验，在正在进行的二甲双胍中加入恩格列净可改善2型糖尿病合并NAFLDS患者的代谢谱、tg-g和fib-4指数以及肝功能测试。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-08-25 DOI: 10.1080/17446651.2025.2550733

Yosra Pahlavan, Majid Ramezani, Majid Mirmohammadkhani, Thozhukat Sathyapalan, Abbas Ziari, Habib Yaribeygi

{"title":"Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial.","authors":"Yosra Pahlavan, Majid Ramezani, Majid Mirmohammadkhani, Thozhukat Sathyapalan, Abbas Ziari, Habib Yaribeygi","doi":"10.1080/17446651.2025.2550733","DOIUrl":"10.1080/17446651.2025.2550733","url":null,"abstract":"Background: SGLT2 inhibitors offer strong glucose-lowering effects in patients with T2DM, but their impact on MAFLD when added to ongoing metformin therapy is not fully understood. This study aimed to evaluate the effects of empagliflozin (a SGLT2 inhibitor) on metabolic profile, liver fibrosis index, and liver function tests in metformin-treated T2DM patients with MAFLD.Research design and methods: This 12-week, prospective, single-center clinical trial enrolled 80 T2DM patients with MAFLD who were already receiving metformin but required further intervention. They received empagliflozin (10 mg/day) in addition to metformin (2000 mg/day). Metabolic parameters including FBS, HbA1c, Chol, TG, LDL, HDL, vitamin D3, ALT, ALP, and AST were measured at baseline and after 12 weeks. Triglyceride-glucose (TG-G) index and fibrosis-4 (FIB-4) score were also calculated.Results: Seventy-four patients completed the trial. Significant reductions were seen in FBS, HbA1c, Chol, LDL, TG, and TG-G index (p < 0.001). Liver markers ALT, AST, and FIB-4 also improved significantly (p < 0.001 and p < 0.02, respectively). Although HDL, ALP, and vitamin D3 increased, these changes were not statistically significant.Conclusion: Adding empagliflozin to ongoing metformin significantly improved metabolic and liver-related markers in T2DM patients with MAFLD, supporting its therapeutic benefit in this population (Clinical Trial Registration: https://irct.behdasht.gov.ir/trial/73164).","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"633-641"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should cannabis be used in the management of endometriosis? 大麻应该用于子宫内膜异位症的治疗吗？

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-10-10 DOI: 10.1080/17446651.2025.2572339

Mike Armour, Justin Sinclair, Callie Seaman, Millie Mardon, Toobah Farooqi, Orit Holtzman, Mathew Leonardi

{"title":"Should cannabis be used in the management of endometriosis?","authors":"Mike Armour, Justin Sinclair, Callie Seaman, Millie Mardon, Toobah Farooqi, Orit Holtzman, Mathew Leonardi","doi":"10.1080/17446651.2025.2572339","DOIUrl":"10.1080/17446651.2025.2572339","url":null,"abstract":"Introduction: Endometriosis is a chronic inflammatory condition that affects around 1 in 7 women of reproductive age. Current medical treatments tend to be sub-optimal to manage the range of symptoms, with low levels of patient satisfaction. Cross-sectional and retrospective data suggests that people with endometriosis are consuming cannabis to help manage their symptoms.Areas covered: This review discusses the evidence for consumption of medicinal cannabis to help manage endometriosis symptoms, including potential mechanisms of action from both animal models and human studies, usage in the community, the current evidence from clinical trials and observational studies, and the safety and potential drug interactions.Expert opinion: While there is a lack of high-quality clinical trial evidence, significant self-reported evidence from cross-sectional surveys and retrospective observational data suggests that those consuming medicinal cannabis report reductions in endometriosis symptoms such as pelvic pain, dysmenorrhea and gastrointestinal symptoms, and improve mental health and sleep. Given the low levels of satisfaction with current treatment options, consideration should be given to trialing medicinal cannabis as part of the interdisciplinary management of endometriosis in those who express interest and who do not demonstrate any significant contraindications.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"497-512"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is a new definition for childhood obesity needed? 儿童肥胖需要一个新的定义吗？

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-10-06 DOI: 10.1080/17446651.2025.2570236

Petur B Juliusson

引用次数: 0

Personalized medicine in acromegaly: insights from the ACROFAST clinical trial. 肢端肥大症的个性化医疗：来自ACROFAST临床试验的见解。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-09-29 DOI: 10.1080/17446651.2025.2561066

Marta Araujo-Castro, Betina Biagetti, Víctor Navas-Moreno, María Bernarda-Iriarte, Rebeca Martínez-Hernández, Elena Valassi, Manel Puig-Domingo, Mónica Marazuela

{"title":"Personalized medicine in acromegaly: insights from the ACROFAST clinical trial.","authors":"Marta Araujo-Castro, Betina Biagetti, Víctor Navas-Moreno, María Bernarda-Iriarte, Rebeca Martínez-Hernández, Elena Valassi, Manel Puig-Domingo, Mónica Marazuela","doi":"10.1080/17446651.2025.2561066","DOIUrl":"10.1080/17446651.2025.2561066","url":null,"abstract":"Introduction: Personalized medicine has gained importance in the management of acromegaly, driven by advances in tumor classification, molecular profiling, and imaging modalities. This approach leads to achieved biochemical control more frequently and in a shorter time frame when compared to the usual trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drug, which is still currently recommended in most clinical guidelines.Areas covered: In this review, we summarize recent advances in personalized medicine for acromegaly, with a particular focus on predictive markers of surgical and medical treatment response. Moreover, we highlight the perspectives gained from the ACROFAST clinical trial, which has contributed with valuable insights into the clinical implementation of individualized therapeutic strategies.Expert opinion: We consider that the future of research in acromegaly lies in the continued advancement and refinement of personalized medicine approaches. ACROFAST has laid critical groundwork by demonstrating how the combination of predictive biomarkers enhances therapeutic outcomes, improving the rate of biochemical remission and in a shorter follow-up period. In addition, the application of artificial intelligence and machine learning algorithms trained on multiomic and clinical datasets may be useful to improve outcomes and reduce the trial-and-error nature of current pharmacologic management of acromegaly.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"539-552"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145185047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-escalation, palliation and end of life care in frail older people with diabetes-a critical review. 衰弱的老年糖尿病患者的降级、缓和和临终关怀——一项重要综述。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2025-11-01 Epub Date: 2025-07-21 DOI: 10.1080/17446651.2025.2535668

I Siqueira, J Jenkinson, P Briggs, H Picker, X Chen, A H Abdelhafiz

{"title":"De-escalation, palliation and end of life care in frail older people with diabetes-a critical review.","authors":"I Siqueira, J Jenkinson, P Briggs, H Picker, X Chen, A H Abdelhafiz","doi":"10.1080/17446651.2025.2535668","DOIUrl":"10.1080/17446651.2025.2535668","url":null,"abstract":"Introduction: Frail older people with diabetes will need regular medications review and individualized care, especially at the final phase of life. Although guidelines are detailed on escalation of medications, there is little detail on how to de-escalate therapy when need arises. In addition, there is no description of patients' criteria in whom de-escalation should be considered.Area covered: In the guidelines, frailty is referred to as one homogeneous group. However, frailty is a metabolically heterogeneous condition with a span of variability in insulin resistance depending on proportional ratios of visceral body fat mass, muscle mass, and total body weight. Therefore, cardiovascular risk and the need for tight targets are variable depending on frailty metabolic phenotype. Taking this into consideration, the phenotype of frailty should be taken into account when considering de-escalation of therapy. Furthermore, de-escalation of cardiovascular therapy will differ by frailty phenotype and underlying cardiovascular risk.Expert opinion: This manuscript addresses the issue of metabolic variability of frailty and suggests three chronological stages, from de-escalation, palliation to end-of-life care in a patient-centered perspective. Future research is required to develop de-escalation pathways and strategies, which will impact on health care costs, patients' safety, and quality of life.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"593-605"},"PeriodicalIF":2.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0